Raise large amounts of capital with an initial public offering, burn cash while navigating clinical trials, then submit a new ...
The State Street SPDR S&P Biotech ETF (XBI) was launched on January 31, 2006, and is a passively managed exchange traded fund designed to offer broad exposure to the Healthcare - Biotech segment of ...
Designed to provide broad exposure to the Healthcare - Biotech segment of the equity market, the iShares Biotechnology ETF (IBB) is a passively managed exchange traded fund launched on February 5, ...
The Direxion Daily S&P Biotech Bear 3X Shares ETF offers -3X daily leverage to the S&P Biotechnology Select Industry Index, primarily attracting short-term traders. LABD has lost 99.98% of its value ...
As we approach the final weeks of 2025, the U.S. healthcare sector has transitioned from a defensive stalwart to a primary market leader. Evidently, while the S&P 500 has delivered a solid return of ...
When it comes to discussing the best ETFs to buy in 2026, the discussion usually starts with tech and artificial intelligence ...